Search

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, [...]

MARLBOROUGH, Mass. and WASHINGTON: Boston Scientific Corporation has issued the following news release: Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE [...]

MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated [...]

BOSTON, MA -- The following information was released by Beth Israel Deaconess Medical Center (BIDMC): First-of-its-kind Trial in US Shows Drug-coated Balloons are a Superior Treatment Option for Patients Undergoing [...]

MARLBOROUGH: Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line treatment for [...]

MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE(TM) Pulsed Field [...]

MARLBOROUGH: Boston Scientific Corporation has issued the following news release: Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENTtm [...]

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ -- [...]

Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass., Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTECTED TAVR [...]

MARLBOROUGH: Boston Scientific Corporation has issued the following news release: Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of [...]

Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: [...]

WASHINGTON, Nov. 18, 2021 /PRNewswire/ -- The Society of Interventional Oncology (SIO) announces the launch of the society's first clinical trial, 'Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective [...]

LAS VEGAS and MARLBOROUGH: Boston Scientific Corporation has issued the following news release: Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic Endovascular System (EKOS system) during a [...]

LAS VEGAS: Boston Scientific Corporation has issued the following news release: Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger Drug-Coated Balloon (DCB) during a late-breaking clinical trial [...]

Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- [...]

Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) [...]

Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism MARLBOROUGH, Mass., Aug. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: [...]

MARLBOROUGH: Boston Scientific Corporation has issued the following news release: Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy [...]

PINNACLE FLX study meets 24-month endpoint, reinforces positive 12-month outcomes with next-generation device for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: [...]

DUBLIN: Research and Markets has issued the following news release: The 'Vagus Nerve Stimulators (VNS) - Medical Devices Pipeline Assessment, 2020' report has been added to ResearchAndMarkets.com's offering 'Vagus Nerve [...]

MARLBOROUGH: Boston Scientific Corporation has issued the following press release: Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere Y-90 Glass Microspheres (TheraSphere) - [...]

MARLBOROUGH: Boston Scientific Corporation announced positive data from the TARGET study of the TheraSphere Y-90 Glass Microspheres (TheraSphere) - a type of radioembolization comprised of millions of microscopic glass beads [...]

Data presented at SIR 2021 confirm safety and dose-efficacy relationship MARLBOROUGH, Mass., March 25, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of [...]

Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., Oct. 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: [...]

Marlborough: Boston Scientific has issued the following press release: Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of [...]

Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., May 8, [...]

SAN FRANCISCO: Boston Scientific has issued the following press release: Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM Subcutaneous [...]

Marlborough: Boston Scientific has issued the following press release: Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA [...]

New data showcasing performance of recently acquired RF balloon-based, single-shot ablation technology LISBON, Portugal and MARLBOROUGH, Mass., March 17, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced data from [...]

BARCELONA, Spain : Boston Scientific Corporation has issued the following press release: Boston Scientific Corporation (NYSE: BSX) announced real-world data from the TRUE-HD study during a late-breaking clinical trial session [...]

New York City: E*TRADE Financial Corporation (ETFC) has issued the following press release: Boston Scientific Corp: * LATE-BREAKING CLINICAL TRIAL DATA FURTHER DEMONSTRATE SAFETY AND EFFECTIVENESS OF THE RHYTHMIA MAPPING [...]

BARCELONA, Spain and MARLBOROUGH, Mass., March 20, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced real-world data from the TRUE-HD study during a late-breaking clinical trial session today at [...]

Byline: JOE CARLSON; STAFF WRITER Boston ScientificÆs ôblockbusterö Synergy stent for opening blocked arteries on the heart commands a higher price than its competitors, but so far the jury is [...]

PARIS and MARLBOROUGH, Mass., May 16, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, [...]

LAS VEGAS, Nov. 2, 2015 /PRNewswire/ -- http://vivaphysicians.org/ , a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, is excited to announce [...]

SAN FRANCISCO (AP) -- The future is unclear for a heart device aimed at preventing strokes in people at high risk of them because of an irregular heartbeat. Early results [...]

Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval MARLBOROUGH, Mass., Sept. 23, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical [...]

Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure MARLBOROUGH, Mass., Aug. 30, 2014 /PRNewswire/ -- Boston Scientific has released the primary [...]

Boston Scientific Shockless Implant Evaluation (SIMPLE) Study Results Presented at Heart Rhythm 2014, the Heart Rhythm Society's 35th Annual Scientific Sessions NATICK, Mass., May 8, 2014 /PRNewswire/ -- A Boston [...]

NATICK, Mass., April 22, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has conducted the first implant in the clinical trial of the next generation ACUITY(TM) X4 left-ventricular (LV) pacing [...]

REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course NATICK, Massachusetts, September 17, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from [...]

NATICK, Mass. Sept. 30 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Food & Drug Administration (FDA) has approved the Magic Wallstent for the treatment of [...]

WATERTOWN, Mass., Jan. 21 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its Mansfield Division has received approval from the Food and Drug Administration to market Synergy, the [...]